Diagnosis and treatment of adrenocortical cancer
Abstract
The goal of investigation is to evaluate the immediate and long-term results of treatment of adrenocortical cancer. Materials and methods: the analysis was applied to the results of examination and treatment of 31 patients with adrenocortical cancer. Results: disease-free for up to 5 years of the disease observed in 29,2% of cases. In 16,1% of cases took place a second surgery for local recurrence of the tumor and (or) distant metastases. Conclusion: surgical intervention remains the only method of radical treatment of adrenocortical cancer. The main conditions for radical surgery should be considered as removing the adrenal gland to the surrounding tissue as well as fiber aortocaval gap. Improving long-term outcome is possible with early detection of the disease, careful dynamic monitoring in the postoperative period, the development of more effective chemotherapy regimens carrying on the testimony of biotherapy, implementation of cytoreductive operations with impossibility of radical intervention.
About the Authors
S. S. Kharnas
The I.M. Sechenov First MSMU
Russian Federation
Russian Federation
MD, prof. of the chair of faculty surgery № 1
L. I. Ippolitov
The I.M. Sechenov First MSMU
Russian Federation
Russian Federation
PhD, head of surgical department № 2 of university hospital № 1
S. P. Vetshev
The I.M. Sechenov First MSMU
Russian Federation
Russian Federation
PhD, associate prof. of the chair of faculty surgery № 1
G. V. Polunin
The I.M. Sechenov First MSMU
Russian Federation
Russian Federation
PhD, surgeon of surgical department № 2 of university hospital № 1
S. V. Stefankov
The I.M. Sechenov First MSMU
Russian Federation
Russian Federation
PhD, oncologist of university hospital № 1
A. S. Slobodyanik
The I.M. Sechenov First MSMU
Russian Federation
Russian Federation
clinical resident of the chair of faculty surgery № 1
A. A. Kovalenko
The I.M. Sechenov First MSMU
Russian Federation
Russian Federation
surgeon of medical-diagnostic department № 1 of university hospital № 1
References
1. Haleblian G.E., Wilson C., Haddad D. Adrenocortical carcinoma: role of laparoscopic surgery in treatment // Expert Rev. Anticancer Ther. — 2007. — Vol. 7. — P. 1295–1300.
2. Libe R., Fratticci A., Bertherat J. Adren ocortical cancer: pathophysiology and clinical management // Endocrine related cancer. — 2007. — Vol. 14. — P. 13–28.
3. TNM: Классификация злокачественных опухолей / Под ред. Собина Л.Х. и др. — М.: «Логосфера», 2011.
4. Давыдов М.И., Стилиди И.С., Клименков А.А. и д р. Певичные и метастатические опухоли надпочечников // Вестник Московского онкологического общества. — 2008. — Вып. 6–8. — С. 3–4.
5. Terzolo M., Angeli A., Fassnacht M. Adjuvant mitota ne treatment for adrenocortical carcinoma // N. Engl. J. Med. — 2007. — Vol. 356. — P. 2372–2380.
6. Fassnacht M., Johanssen S., Quinkler M. Limited prognostic value of the 2004 International Union Against Cancer staging classifi cation for adrenocortical carcinoma. — Cancer, 2009. — Vol. 115. — P. 243–250.
7. Abma E.M., Kluin P.M., Dullaart R.P. Malignant aldosteroneproducing adrenal tumour: reoccurrence with glucocorticoid excess without hyperaldosteronism // Neth. J. Med. — 2008. — Vol. 66. — P. 252–255.
8. Johanssen S., Fassnacht M., Brix D. Adrenocortical carcinoma. D iagnostic work-up and treatment // Urologe A. — 2008. — Vol. 47. — P. 172–181.
9. Khan S., Imtiaz K. Adrenocortical carcinoma: a diagnostic and treat ment dilemma // British J. of Hosp. Med. — 2009. — Vol. 70. — P. 46–47.
10. Miller B.S., Ammori J.B., Gauger P.G. et al. Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma // World J. Surg. — 2010. — Vol. 34. — P. 1380–1385.
11. Патютко Ю.И., Гахраманов А.Д. Успешное хирургическое лечение рака надпочеч ника с неоднократным метастазированием // Хирургия. — 2008. — № 12. — С. 51–53.
12. Lindholm J., Juui S., Jorgensen J.O.L. et al. Incidence and late prognosis of Cushing’s syndrome: a population-based study // J. Clin. Endocrinol. Metab. — 2001. — Vol. 86. — P. 117–123.
13. Porterfi eld J.R., Chow J.T., Atkinson J.L.D. et al. Surgery for Cushing’s syndrome: a historical review and recent ten-year experience // World J. Surg. — 2008. — Vol. 32. — P. 659–677.
14. Fassnacht M, Allolio B. What is the best approach to an apparently nonmetastatic adreno cortical carcinoma? // Clin. Endocrinol. — 2010. — Vol. 73. — P. 561–565.
15. Fassnacht M., Terzolo M., Allolio B. et al. Combination chemotherapy in advanced adrenocorti cal carcinoma // N. Engl. J. Med. — 2012. — Vol. 366. — P. 2189–2197.
16. http://www.minzdravsoc.ru/health/orffs/0
17. Barlaskar F.M., Spalding A.C., Heaton J.H. et al. P reclinical targeting of the type I insulin-li ke growth factor receptor in adrenocortical carcinoma // J. Clin. Endocrinol. Metab. — 2009. — Vol. 94. — P. 204–212.
18. Kroiss M., Reuss M., Kühner D. Sunitinib inhibits cell proliferation and alters steroidogenesis by d own-Regulation of HSD3B2 in adrenocortical carcinoma cells // Front. Endocrinol. — 2011. — Vol. 2. — P. 27.
Review
Views: 165
Email this article 